 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
| «12345678910 |
- imipenem/relebactam / Merck (MSD), relebactam (MK-7655) / Merck (MSD)
Imipenem-relebactam efficiently inhibits D179 variants of the KPC-2 beta-lactamase (Arena 2) - Apr 5, 2019 - Abstract #ECCMID2019ECCMID_3694;
The D179N variant is more versatile than D179Y. IMI/REL overcomes the resistance conferred by the KPC-2 D179N variant, suggesting that this therapeutic combination will be potent against clinical isolates harboring KPC-2 and its evolutionary derivatives.
- imipenem/relebactam / Merck (MSD), relebactam (MK-7655) / Merck (MSD)
In vitro activity and selection of imipenem-relebactam resistance against carbapenem-resistant Enterobacteriaceae (Arena 2) - Apr 5, 2019 - Abstract #ECCMID2019ECCMID_3529;
IMI/REL MICs are higher against clinical KPC-Kp with ompK36 mutations, which also arose during passage experiments. Selection for IMI/REL resistance against KPC-Kp may occur at lower frequencies than CZA; however, additional experiments are needed to confirm these findings.
- imipenem/relebactam / Merck (MSD), relebactam (MK-7655) / Merck (MSD)
Stability of imipenem-relebactam against Pseudomonas aeruginosa beta-lactam (including recently introduced combinations) resistance mechanism (Arena 2) - Apr 5, 2019 - Abstract #ECCMID2019ECCMID_3443;
Selection for IMI/REL resistance against KPC-Kp may occur at lower frequencies than CZA; however, additional experiments are needed to confirm these findings. Imipenem/relebactam adds valuable potential to our antipseudomonal arsenal, overcoming the most relevant mutation-driven resistance mechanisms, including those leading to ceftolozane/tazobactam and ceftazidime/avibactam resistance development.
- imipenem/relebactam / Merck (MSD), relebactam (MK-7655) / Merck (MSD)
Rapid detection of imipenem-relebactam susceptibility by a biochemical method () - Apr 5, 2019 - Abstract #ECCMID2019ECCMID_2675;
Results regarding the susceptibility or resistance to imipenem-relebactam were in agreement with the MICs. Neither of the KPC-producers tested were resistant to imipenem-relebactam.
- imipenem/relebactam / Merck (MSD), relebactam (MK-7655) / Merck (MSD)
Rapid detection of imipenem-relebactam susceptibility by MALDI-TOF mass spectrometry () - Apr 5, 2019 - Abstract #ECCMID2019ECCMID_2650;
Results regarding the susceptibility or resistance to imipenem-relebactam were in agreement with the MICs. Neither of the KPC-producers tested were resistant to imipenem-relebactam.
- imipenem/relebactam / Merck (MSD), relebactam (MK-7655) / Merck (MSD)
Relebactam and imipenem clearance during ex vivo continuous renal replacement therapy () - Apr 5, 2019 - Abstract #ECCMID2019ECCMID_2288;
Imipenem and relebactam are not removed by adsorption but readily cross the hemodiafilter membrane in CH and CHD. Dosage adjustment of imipenem/relebactam is likely required for critically ill patients receiving CRRT.
- A new development in drug-resistant Pseudomonas in the USA; blaKPC finds a new niche conferring resistance to carbapenems and new beta-lactam/beta-lactamase inhibitor combinations () - Apr 5, 2019 - Abstract #ECCMID2019ECCMID_2287;
Subsequent plasmid extraction, typing, and electroporation into E.coli indicates the possibility of plasmid-mediated gene dissemination. Additional blaKPC spread to XDR P. aeruginosa would impact empiric antibiotic selection and further limit treatment options against these isolates.
- Retrospective cohort of Serratia marcescens KPC-2 producer isolates from southern Brazil () - Apr 5, 2019 - Abstract #ECCMID2019ECCMID_1681;
Amikacin was the mostly active agent and a reasonable treatment in this setting. Even though incidence seems to be decreasing, treatment of these conditions is still challenging, as β-lactam-avibactam combinations and imipenem-relebactam are not widely available in low and middle-income countries.
- imipenem/relebactam / Merck (MSD), relebactam (MK-7655) / Merck (MSD)
Identification of beta-lactamases in Enterobacteriaceae with varied levels of susceptibility to imipenem/relebactam collected for the SMART surveillance programme, 2015-2017 () - Apr 5, 2019 - Abstract #ECCMID2019ECCMID_1477;
IMI/REL maintained activity against commonly detected genotypes of BL expressing NPE. IMI/REL could provide an important new therapeutic option against class A and C expressing Enterobacteriaceae.
- imipenem/relebactam / Merck (MSD), relebactam (MK-7655) / Merck (MSD)
Activity of imipenem-relebactam and comparators against Enterobacteriaceae and Pseudomonas aeruginosa from hospitalised patients in Europe - SMART 2017 () - Apr 5, 2019 - Abstract #ECCMID2019ECCMID_1438;
Overall, IMI/REL was active against 98% of NPE and 90% of PA isolates, 2-28 percentage points higher than comparator β-lactams. Susceptibility was lower in countries with higher percentages of MBLs, OXA-48-like and GES carbapenemases, the β-lactamases largely responsible for nonsusceptibility to IMI/REL.
- imipenem/relebactam / Merck (MSD), meropenem / Generic mfg., Daewon Pharmaceutical, relebactam (MK-7655) / Merck (MSD)
In vitro activity of imipenem/relebactam and comparator agents against Gram-negative isolates recovered from cancer patients () - Apr 5, 2019 - Abstract #ECCMID2019ECCMID_1387;
Except for S. maltophilia and MDR P. aeruginosa, the percent susceptibility of IPM/REL was at least 90%. These data suggest that IPM/REL should be clinically investigated for the treatment of infections in cancer patients.
- imipenem/relebactam / Merck (MSD), relebactam (MK-7655) / Merck (MSD)
Activity of imipenem-relebactam in clinical isolates of Enterobacteriaceae obtained from a national study in Spain () - Apr 5, 2019 - Abstract #ECCMID2019ECCMID_1386;
In addition, IMI/REL showed the lowest MIC50/90 among the 17 antimicrobials. For the subgroup of KPC-producing isolates IMI/REL had the highest activity being all the isolates susceptible to the antimicrobial combination.
- imipenem/relebactam / Merck (MSD), relebactam (MK-7655) / Merck (MSD)
Activity of imipenem-relebactam against KPC-positive Enterobacteriaceae isolates from Europe: SMART 2015-2017 () - Apr 5, 2019 - Abstract #ECCMID2019ECCMID_1384;
IMI/REL maintained activity across the most commonly detected genotypes and against colistin-resistant isolates. IMI/REL could provide an important new therapeutic option against KPC+ isolates.